Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Nat Rev Drug Discov. 2009 Dec;8(12):982–1001. doi: 10.1038/nrd2983

Figure 6. Modulators of KV10.1 and KV11.1.

Figure 6

Kv10.1 and Kv11.1 inhibitors:(40), astemizole199–202; (41), imipramine199; (42) dofetilide. Kv10.1 inhibitors have been proposed for the treatment of cancer9,179. KV11.1 (hERG) inhibitors prolong the QT interval and can be both antiarrythmic and proarrythmic (e.g. recall of the antihistamine astemizole). KV11.1 activators: (43) NS1643 (Neurosearch)208; (44) NS3623 (Neurosearch)209; (45), RPR260243 (Sanofi-Aventis)210; (46), PD307243 (GlaxoSmithKline)211; (47), A935143 (Abbott Laboratories)212. KV11.1 activators have been proposed as potential antiarrythmics205.